SEC Form 4 · accession 0001209191-18-054897
Insys Therapeutics, Inc. · INSY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark E Nance
Officer — Chief Legal Officer & Gen Cnsl
Period of report
Oct 10, 2018
Accepted (ET)
Oct 12, 2018 · 4:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001516479
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 10, 2018 | A | 15,000 | $0.00 | A | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $8.61 | Oct 10, 2018 | A | 100,000 | A | — | Oct 9, 2028 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F1The option vests in 48 equal monthly installments and will be fully vested and exercisable on October 10, 2022.